This rejection was mainly due to NK cell response and depends on the MHC class I peptides presented by ERAP1-silenced tumor cells, because replacement of the endogenous peptides with high-affinity peptides was sufficient to restore an NK protective effect of MHC class I through the NK inhibitory receptor Ly49C/I. Here, ERAP1 is linked to neoplasm.